

Flora Zagouri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1030780/publications.pdf>

Version: 2024-02-01

286
papers

4,363
citations

126907

33
h-index

189892

50
g-index

297
all docs

297
docs citations

297
times ranked

6396
citing authors

#	ARTICLE	IF	CITATIONS
1	Trastuzumab administration during pregnancy: a systematic review and meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2013, 137, 349-357.	2.5	146
2	Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. <i>Annals of Oncology</i> , 2019, 30, 1601-1612.	1.2	146
3	Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. <i>Annals of Oncology</i> , 2013, 24, 647-654.	1.2	117
4	Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 13-22.	2.5	114
5	Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. <i>BMC Cancer</i> , 2009, 9, 390.	2.6	90
6	Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma. <i>Radiology</i> , 2017, 282, 484-493.	7.3	81
7	Platinum Derivatives During Pregnancy in Cervical Cancer. <i>Obstetrics and Gynecology</i> , 2013, 121, 337-343.	2.4	76
8	High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. <i>British Journal of Cancer</i> , 2013, 108, 1100-1105.	6.4	69
9	Molecularly targeted therapies in cervical cancer. A systematic review. <i>Gynecologic Oncology</i> , 2012, 126, 291-303.	1.4	68
10	Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development. <i>Breast</i> , 2012, 21, 534-538.	2.2	66
11	Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation. <i>Oncologist</i> , 2017, 22, 667-679.	3.7	62
12	Hsp90 inhibitors in breast cancer: A systematic review. <i>Breast</i> , 2013, 22, 569-578.	2.2	59
13	Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. <i>Leukemia and Lymphoma</i> , 2014, 55, 2018-2023.	1.3	57
14	Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. <i>Leukemia</i> , 2014, 28, 2075-2079.	7.2	57
15	Taxanes for Breast Cancer During Pregnancy: A Systematic Review. <i>Clinical Breast Cancer</i> , 2013, 13, 16-23.	2.4	56
16	Increased expression of macrophage inflammatory protein-1 α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. <i>Leukemia</i> , 2009, 23, 2177-2181.	7.2	54
17	Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. <i>Oncotarget</i> , 2016, 7, 5074-5087.	1.8	54
18	Cancer in pregnancy: disentangling treatment modalities. <i>ESMO Open</i> , 2016, 1, e000016.	4.5	51

#	ARTICLE	IF	CITATIONS
19	Risk Factors for Multiple Myeloma: A Systematic Review of Meta-Analyses. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 563-577.e3.	0.4	50
20	Heat Shock Protein 90 (Hsp90) Expression and Breast Cancer. <i>Pharmaceuticals</i> , 2012, 5, 1008-1020.	3.8	49
21	Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. <i>British Journal of Cancer</i> , 2013, 108, 2259-2263.	6.4	48
22	Cholangiocarcinoma: principles and current trends. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2011, 10, 10-20.	1.3	47
23	Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. <i>Annals of Oncology</i> , 2022, 33, 616-627.	1.2	44
24	Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial. <i>Annals of Oncology</i> , 2017, 28, 1842-1848.	1.2	43
25	Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma. <i>World Journal of Surgical Oncology</i> , 2007, 5, 57.	1.9	41
26	Pain in different methods of breast biopsy: Emphasis on vacuum-assisted breast biopsy. <i>Breast</i> , 2008, 17, 71-75.	2.2	40
27	Endometrial Cancer: What Is New in Adjuvant and Molecularly Targeted Therapy?. <i>Obstetrics and Gynecology International</i> , 2010, 2010, 1-11.	1.3	40
28	Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, e212-e219.	2.4	39
29	Intrathecal administration of anti-HER2 treatment for the treatment of meningeal carcinomatosis in breast cancer: A metanalysis with meta-regression. <i>Cancer Treatment Reviews</i> , 2020, 88, 102046.	7.7	39
30	Minimizing underestimation rate of microcalcifications excised via vacuum-assisted breast biopsy: a blind study. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 397-402.	2.5	38
31	Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel antimyeloma therapies. <i>European Journal of Haematology</i> , 2017, 99, 409-414.	2.2	37
32	HSP90, HSPA8, HIF-1 alpha and HSP70-2 polymorphisms in breast cancer: a case-control study. <i>Molecular Biology Reports</i> , 2012, 39, 10873-10879.	2.3	36
33	Treatment of early uterine sarcomas: disentangling adjuvant modalities. <i>World Journal of Surgical Oncology</i> , 2009, 7, 38.	1.9	35
34	mTOR inhibitors in breast cancer: A systematic review. <i>Gynecologic Oncology</i> , 2012, 127, 662-672.	1.4	34
35	Fulvestrant and male breast cancer: a pooled analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 149, 269-275.	2.5	34
36	Taxanes for Ovarian Cancer during Pregnancy: A Systematic Review. <i>Oncology</i> , 2012, 83, 234-238.	1.9	33

#	ARTICLE	IF	CITATIONS
37	How we treat endocrine complications of immune checkpoint inhibitors. <i>ESMO Open</i> , 2021, 6, 100011.	4.5	32
38	Hsp90 in the continuum of breast ductal carcinogenesis: Evaluation in precursors, preinvasive and ductal carcinoma lesions. <i>BMC Cancer</i> , 2010, 10, 353.	2.6	31
39	Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. <i>European Journal of Haematology</i> , 2014, 92, 308-312.	2.2	31
40	Aromatase inhibitors in male breast cancer: a pooled analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 141-147.	2.5	31
41	The emerging role of BET inhibitors in breast cancer. <i>Breast</i> , 2020, 53, 152-163.	2.2	31
42	Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2021, 14, 86.	17.0	31
43	TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. <i>Oncotarget</i> , 2016, 7, 32731-32753.	1.8	30
44	Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers. <i>Cancer Genomics and Proteomics</i> , 2017, 14, 181-195.	2.0	30
45	VEGF and Id-1 in pancreatic adenocarcinoma: Prognostic significance and impact on angiogenesis. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1331-1337.	1.0	29
46	Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study. <i>PLoS ONE</i> , 2015, 10, e0140293.	2.5	29
47	Management of uterine sarcomas and prognostic indicators: real world data from a single-institution. <i>BMC Cancer</i> , 2018, 18, 1247.	2.6	29
48	The Role of CXCL13 and CXCL9 in Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, e36-e53.	2.4	29
49	Immune checkpoint inhibitor administration during pregnancy: a case series. <i>ESMO Open</i> , 2021, 6, 100262.	4.5	29
50	Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial. <i>Annals of Oncology</i> , 2016, 27, 1733-1739.	1.2	28
51	Management of advanced prostate cancer: A systematic review of existing guidelines and recommendations. <i>Cancer Treatment Reviews</i> , 2019, 73, 54-61.	7.7	28
52	Prognostic role of microRNAs in breast cancer: A systematic review. <i>Oncotarget</i> , 2019, 10, 7156-7178.	1.8	28
53	Molecularly targeted therapies in unresectable-metastatic gastric cancer. A systematic review. <i>Cancer Treatment Reviews</i> , 2011, 37, 599-610.	7.7	27
54	Does Pregnancy-Associated Breast Cancer Imply a Worse Prognosis? A Matched Case-Case Study. <i>Breast Care</i> , 2013, 8, 203-207.	1.4	27

#	ARTICLE	IF	CITATIONS
55	Molecularly Targeted Therapies in Metastatic Pancreatic Cancer. <i>Pancreas</i> , 2013, 42, 760-773.	1.1	26
56	The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping. <i>Breast</i> , 2014, 23, 234-243.	2.2	26
57	Discrepancies between ESMO and NCCN breast cancer guidelines: An Appraisal. <i>Breast</i> , 2015, 24, 513-523.	2.2	26
58	Emerging antibodies for the treatment of multiple myeloma. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 225-237.	2.4	25
59	Is antibiotic use a risk factor for breast cancer? A meta-analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2010, 19, 1101-1107.	1.9	24
60	Effects of Lazaroids on Intestinal Ischemia and Reperfusion Injury in Experimental Models. <i>Journal of Surgical Research</i> , 2011, 166, 265-274.	1.6	24
61	The Genomic Profile of Pregnancy-Associated Breast Cancer: A Systematic Review. <i>Frontiers in Oncology</i> , 2020, 10, 1773.	2.8	23
62	Clinical perspectives of BET inhibition in ovarian cancer. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 237-249.	4.4	23
63	Serum Proteomic Signatures of Male Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 129-137.	2.0	22
64	Bilateral synchronous breast carcinomas followed by a metastasis to the gallbladder: a case report. <i>World Journal of Surgical Oncology</i> , 2007, 5, 101.	1.9	21
65	Prostate Cancer with Metastasis to the Omentum and Massive Ascites: A Rare Manifestation of a Common Disease. <i>Onkologie</i> , 2009, 32, 758-761.	0.8	21
66	Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. <i>Gynecologic Oncology</i> , 2017, 144, 65-71.	1.4	21
67	Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial. <i>PLoS ONE</i> , 2018, 13, e0200302.	2.5	21
68	Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group. <i>ESMO Open</i> , 2020, 5, e000774.	4.5	20
69	“The emerging role of capivasertib in breast cancer” <i>Breast</i> , 2022, 63, 157-167.	2.2	20
70	Fulvestrant and male breast cancer: a case series. <i>Annals of Oncology</i> , 2013, 24, 265-266.	1.2	19
71	Adding the power of iodinated contrast media to the credibility of mammography in breast cancer diagnosis. <i>British Journal of Radiology</i> , 2016, 89, 20160397.	2.2	19
72	Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1549-1564.	4.2	19

#	ARTICLE	IF	CITATIONS
73	Current clinical practice guidelines on chemotherapy and radiotherapy for the treatment of non-metastatic muscle-invasive urothelial cancer: A systematic review and critical evaluation by the Hellenic Genito-Urinary Cancer Group (HGUCG). <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 36-49.	4.4	18
74	IgD Myeloma: Clinical Features and Outcome In The Era Of Novel Agents. <i>Blood</i> , 2013, 122, 1935-1935.	1.4	18
75	Soluble human leukocyte antigen-G expression in patients with ductal and lobular breast malignancy. <i>Anticancer Research</i> , 2012, 32, 1021-6.	1.1	18
76	Is zero underestimation feasible? Extended Vacuum-assisted breast biopsy in solid lesions – a blind study. <i>World Journal of Surgical Oncology</i> , 2007, 5, 53.	1.9	17
77	Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: A single institution experience. <i>Gynecologic Oncology</i> , 2011, 123, 37-42.	1.4	17
78	Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer. <i>Hellenic Journal of Cardiology</i> , 2017, 58, 215-219.	1.0	17
79	Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. <i>Translational Oncology</i> , 2017, 10, 589-598.	3.7	17
80	Trastuzumab administration during pregnancy: an update. <i>BMC Cancer</i> , 2021, 21, 463.	2.6	17
81	Gastrointestinal stromal tumor causing small bowel intussusception in a patient with Crohn's disease. <i>World Journal of Gastroenterology</i> , 2009, 15, 5224.	3.3	17
82	Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias. <i>American Journal of Hematology</i> , 2011, 86, 882-884.	4.1	16
83	Serum CA 125, CA 15-3, CEA, and CA 19-9: a prognostic factor for uterine carcinosarcomas?. <i>Archives of Gynecology and Obstetrics</i> , 2013, 287, 97-102.	1.7	16
84	Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 307-321.	2.5	16
85	Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study. <i>Journal of Translational Medicine</i> , 2015, 13, 171.	4.4	15
86	SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors. <i>Breast</i> , 2021, 60, 58-61.	2.2	15
87	Diagnosing Papillary Lesions Using Vacuum-Assisted Breast Biopsy: Should Conservative or Surgical Management Follow?. <i>Oncology Research and Treatment</i> , 2008, 31, 653-656.	1.2	14
88	Ocular Surface Disease in Breast Cancer Patients Using Aromatase Inhibitors. <i>Breast Journal</i> , 2016, 22, 561-563.	1.0	14
89	Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. <i>Journal of Translational Medicine</i> , 2017, 15, 30.	4.4	14
90	Protein expression patterns of cell cycle regulators in operable breast cancer. <i>PLoS ONE</i> , 2017, 12, e0180489.	2.5	14

#	ARTICLE	IF	CITATIONS
91	Taxanes during pregnancy in cervical cancer: A systematic review and pooled analysis. <i>Cancer Treatment Reviews</i> , 2019, 79, 101885.	7.7	13
92	Opposite Prognostic Impact of Single PTEN-loss and PIK3CA Mutations in Early High-risk Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 195-206.	2.0	13
93	Paving the way for changing perceptions in breast surgery: a systematic literature review focused on oncological and aesthetic outcomes of oncoplastic surgery for breast cancer. <i>Breast Cancer</i> , 2019, 26, 416-427.	2.9	13
94	The Role of the Hippo Pathway in Breast Cancer Carcinogenesis, Prognosis, and Treatment: A Systematic Review. <i>Breast Care</i> , 2021, 16, 6-15.	1.4	13
95	Molecular markers in epithelial ovarian cancer: their role in prognosis and therapy. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2010, 31, 268-77.	0.2	13
96	Vacuum-assisted breast biopsy: more cores, more hematomas?. <i>In Vivo</i> , 2011, 25, 703-5.	1.3	13
97	Breast ductal endoscopy: how many procedures qualify?. <i>BMC Research Notes</i> , 2009, 2, 115.	1.4	12
98	Decreased Hsp90 expression in infiltrative lobular carcinoma: an immunohistochemical study. <i>BMC Cancer</i> , 2010, 10, 409.	2.6	12
99	Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy. <i>Cancer Medicine</i> , 2018, 7, 5066-5082.	2.8	12
100	Diffusion-Weighted Imaging Improves Accuracy in the Diagnosis of MRI Patterns of Marrow Involvement in Newly Diagnosed Myeloma: Results of a Prospective Study in 99 Patients. <i>Blood</i> , 2015, 126, 4178-4178.	1.4	12
101	Challenges in managing breast cancer during pregnancy. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 1, S62-7.	1.4	12
102	Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NltCHE trial (MITO 33). <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1369-1373.	2.5	12
103	Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival. <i>Frontiers in Oncology</i> , 2022, 12, 847917.	2.8	12
104	Physical Exercise Restrains Cancer Progression through Muscle-Derived Factors. <i>Cancers</i> , 2022, 14, 1892.	3.7	12
105	Breast Ductal Endoscopy: Do Not Neglect Education. <i>Onkologie</i> , 2008, 31, 136-136.	0.8	11
106	Pertuzumab in Breast Cancer: A Systematic Review. <i>Clinical Breast Cancer</i> , 2013, 13, 315-324.	2.4	11
107	Cyclin D1, p16 ^{INK4A} and p27 ^{Kip1} in pancreatic adenocarcinoma: assessing prognostic implications through quantitative image analysis. <i>Apmis</i> , 2014, 122, 1230-1239.	2.0	11
108	Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review. <i>OncoTargets and Therapy</i> , 2015, 8, 2187.	2.0	11

#	ARTICLE	IF	CITATIONS
109	Electroretinographic and optical coherence tomography findings in breast cancer patients using aromatase inhibitors. <i>Cutaneous and Ocular Toxicology</i> , 2016, 35, 13-20.	1.3	11
110	Breast lymphoma in a patient with B-cell Non Hodgkin Lymphoma: A case report study. <i>International Journal of Surgery Case Reports</i> , 2017, 40, 1-5.	0.6	11
111	Female breast cancer in Europe: statistics, diagnosis and treatment modalities. <i>Journal of Thoracic Disease</i> , 2014, 6, 589-90.	1.4	11
112	Cutaneous metastasis of signet-ring gastric adenocarcinoma to the breast with unusual clinicopathological features. <i>Anticancer Research</i> , 2011, 31, 2373-8.	1.1	11
113	Vacuum-assisted breast biopsy: The value and limitations of cores with microcalcifications. <i>Pathology Research and Practice</i> , 2007, 203, 563-566.	2.3	10
114	Giant Cell Arteritis of the Breast and Breast Cancer: Paraneoplastic Manifestation or Concomitant Disease? A Case Report. <i>Oncology Research and Treatment</i> , 2008, 31, 685-688.	1.2	10
115	Macular oedema due to letrozole: A first case report. <i>Australasian journal of optometry, The</i> , 2012, 95, 646-650.	1.3	10
116	Mucinous Tubular and Spindle Cell Carcinoma of the Kidney:A Case Report. <i>Case Reports in Oncology</i> , 2012, 5, 347-353.	0.7	10
117	Association of VEGF-A Splice Variant mRNA Expression With Outcome in Bevacizumab-Treated Patients With Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2014, 14, 330-338.	2.4	10
118	The effect of U-74389G on pancreas ischemiaâ€“reperfusion injury in a swine model. <i>Journal of Surgical Research</i> , 2014, 187, 450-457.	1.6	10
119	Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. <i>International Journal of Cancer</i> , 2019, 145, 559-568.	5.1	10
120	Long-Term Neurodevelopmental Outcome of Children after in Utero Exposure to Chemotherapy. <i>Cancers</i> , 2020, 12, 3623.	3.7	10
121	Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 361-367.	0.4	10
122	MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment. <i>Cancers</i> , 2021, 13, 4114.	3.7	10
123	Occupational Exposure and Multiple Myeloma Risk: An Updated Review of Meta-Analyses. <i>Journal of Clinical Medicine</i> , 2021, 10, 4179.	2.4	10
124	Pembrolizumab in endometrial cancer: Where we stand now (Review). <i>Oncology Letters</i> , 2021, 22, 821.	1.8	10
125	Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors. <i>Vaccines</i> , 2021, 9, 1148.	4.4	10
126	Update Overview of the Role of Angiopoietins in Lung Cancer. <i>Medicina (Lithuania)</i> , 2021, 57, 1191.	2.0	10

#	ARTICLE	IF	CITATIONS
127	Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy. <i>Journal of Ovarian Research</i> , 2021, 14, 148.	3.0	10
128	Genetic variability of the HPV16 early genes and LCR. Present and future perspectives. <i>Expert Reviews in Molecular Medicine</i> , 2021, 23, e19.	3.9	10
129	Atypical ductal hyperplasia: A way to minimize underestimation in vacuum-assisted breast biopsy?. <i>Breast</i> , 2008, 17, 6.	2.2	9
130	Volume of blood suctioned during vacuum-assisted breast biopsy predicts later hematoma formation. <i>BMC Research Notes</i> , 2010, 3, 70.	1.4	9
131	MMP-2 $\text{rs}1306$ polymorphism in breast cancer: a case-control study in a South European population. <i>Molecular Biology Reports</i> , 2013, 40, 5035-5040.	2.3	9
132	An update on the use of lenalidomide for the treatment of multiple myeloma. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 1865-1877.	1.8	9
133	Prognostic significance of miR-34 rs4938723 C polymorphism in triple negative breast cancer patients. <i>Clinical Biochemistry</i> , 2019, 68, 9-14.	1.9	9
134	Carotid Disease and Ageing: A Literature Review on the Pathogenesis of Vascular Senescence in Older Subjects. <i>Current Gerontology and Geriatrics Research</i> , 2020, 2020, 1-10.	1.6	9
135	Germline mutations in a clinic-based series of pregnancy associated breast cancer patients. <i>BMC Cancer</i> , 2021, 21, 572.	2.6	9
136	The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy. <i>Anticancer Research</i> , 2017, 37, 2947-2957.	1.1	9
137	Determination of FABP4, RBP4 and the MMP9/NGAL complex in the serum of women with breast cancer. <i>Oncology Letters</i> , 2020, 21, 85.	1.8	9
138	SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition. <i>Cancers</i> , 2022, 14, 2796.	3.7	9
139	Immunohistochemical expression of estrogen receptors alpha and beta in lobular neoplasia. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 451, 893-897.	2.8	8
140	Sarcomas of the Fallopian Tube: Disentangling a Rare Entity. <i>Onkologie</i> , 2011, 34, 132-138.	0.8	8
141	HTERT MNS16A polymorphism in breast cancer: a case-control study. <i>Molecular Biology Reports</i> , 2012, 39, 10859-10863.	2.3	8
142	Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer. <i>Breast Care</i> , 2014, 9, 6-6.	1.4	8
143	Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes. <i>PLoS ONE</i> , 2016, 11, e0163138.	2.5	8
144	Flow-Mediated Dilation of Brachial Artery as a Screening Tool for Anthracycline-Induced Cardiotoxicity. <i>Journal of the American College of Cardiology</i> , 2017, 70, 3072.	2.8	8

#	ARTICLE	IF	CITATIONS
145	Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials. <i>Clinical Breast Cancer</i> , 2018, 18, 53-62.e3.	2.4	8
146	Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?. <i>ESMO Open</i> , 2019, 4, e000479.	4.5	8
147	Secondary Alopecia Neoplastica Mimicking Alopecia Areata following Breast Cancer. <i>Case Reports in Oncology</i> , 2020, 13, 627-632.	0.7	8
148	Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes—a Hellenic Cooperative Oncology Group (HeCOG) Trial. <i>British Journal of Cancer</i> , 2020, 123, 355-361.	6.4	8
149	The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. <i>Vaccines</i> , 2021, 9, 422.	4.4	8
150	Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review. <i>Annals of Translational Medicine</i> , 2020, 8, 1603-1603.	1.7	8
151	The effect of nitric oxide synthases inhibitors on inflammatory bowel disease in a rat model. <i>In Vivo</i> , 2004, 18, 513-6.	1.3	8
152	Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial. <i>Anticancer Research</i> , 2015, 35, 4023-36.	1.1	8
153	Heat shock protein90 in lobular neoplasia of the breast. <i>BMC Cancer</i> , 2008, 8, 312.	2.6	7
154	Downgrading BIRADS 3 to BIRADS 2 category using a computer-aided microcalcification analysis and risk assessment system for early breast cancer. <i>Computers in Biology and Medicine</i> , 2010, 40, 853-859.	7.0	7
155	Prospective Evaluation of Health-Related Quality of Life in a Homogeneous Mediterranean Group of Colorectal Cancer Patients. <i>American Surgeon</i> , 2010, 76, 502-508.	0.8	7
156	Breast Cancer in Women Aged 25 Years and Younger. <i>Obstetrics and Gynecology</i> , 2013, 121, 1235-1240.	2.4	7
157	Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma. <i>Annals of Hematology</i> , 2017, 96, 1707-1714.	1.8	7
158	Chemotherapy resumption in ovarian cancer patient diagnosed with COVID-19. <i>Gynecologic Oncology Reports</i> , 2020, 33, 100615.	0.6	7
159	A Case Series of BCOR Sarcomas With a New Splice Variant of <i>BCOR/CCNB3</i> Fusion Gene. <i>In Vivo</i> , 2020, 34, 2947-2954.	1.3	7
160	First Line Gemcitabine/Pazopanib in Locally Advanced and/or Metastatic Biliary Tract Carcinoma. A Hellenic Cooperative Oncology Group Phase II Study. <i>Anticancer Research</i> , 2020, 40, 929-938.	1.1	7
161	TP53 mutations determined by targeted NGS in breast cancer: a case-control study. <i>Oncotarget</i> , 2021, 12, 2206-2214.	1.8	7
162	Cardiovascular toxicity of breast cancer treatment: an update. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 15-24.	2.3	7

#	ARTICLE	IF	CITATIONS
163	Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review. <i>Cancers</i> , 2021, 13, 465.	3.7	7
164	Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study. <i>Oncotarget</i> , 2018, 9, 36906-36913.	1.8	7
165	Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 117-118.	3.9	7
166	Pain during vacuum-assisted breast biopsy: Are there any predictors?. <i>Breast</i> , 2008, 17, 592-595.	2.2	6
167	Vacuum-assisted breast biopsy: an easy-to-learn procedure?. <i>American Journal of Surgery</i> , 2008, 196, 798.	1.8	6
168	Vacuum-assisted breast biopsy: more cores, more scars?. <i>Clinical Radiology</i> , 2008, 63, 736-737.	1.1	6
169	Breast self-examination and adherence to mammographic follow-up: an intriguing diptych after benign breast biopsy. <i>European Journal of Cancer Prevention</i> , 2010, 19, 71-72.	1.3	6
170	Serum MMPs and TIMPs: May be predictors of breast carcinogenesis?. <i>Clinica Chimica Acta</i> , 2011, 412, 537-540.	1.1	6
171	Laparoscopic Repair of Giant Paraesophageal Hernia with Synthetic Mesh: 45 Consecutive Cases. <i>American Surgeon</i> , 2012, 78, 432-435.	0.8	6
172	Vascular endothelial growth factor polymorphisms and clinical outcome in patients with metastatic breast cancer treated with weekly docetaxel. <i>Pharmacogenomics Journal</i> , 2014, 14, 248-255.	2.0	6
173	Clinical Perspectives of ERCC1 in Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8829.	4.1	6
174	Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal Treatment and CDK 4/6 Inhibitors or Everolimus. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 638895.	2.4	6
175	Immunotherapy in HER2-Positive Breast Cancer: A Systematic Review. <i>Breast Care</i> , 2022, 17, 63-70.	1.4	6
176	Acute intermittent porphyria in pregnancy: a common misdiagnosis. <i>Clinical and Experimental Obstetrics and Gynecology</i> , 2010, 37, 256-60.	0.2	6
177	Serum levels of HSP90 in the continuum of breast ductal and lobular lesions. <i>In Vivo</i> , 2011, 25, 669-72.	1.3	6
178	Low protein expression of MET in ER-positive and HER2-positive breast cancer. <i>Anticancer Research</i> , 2014, 34, 1227-31.	1.1	6
179	Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2016, 36, 2365-78.	1.1	6
180	Secondary breast lymphoma diagnosed by vacuum-assisted breast biopsy: a case report. <i>Journal of Medical Case Reports</i> , 2007, 1, 113.	0.8	5

#	ARTICLE	IF	CITATIONS
181	Biopsy Method: A Major Predictor of Adherence After Benign Breast Biopsy?. American Journal of Roentgenology, 2009, 193, W452-W457.	2.2	5
182	Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?. OncoTargets and Therapy, 2015, 8, 1843.	2.0	5
183	Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy. Gynecologic Oncology, 2020, 157, 599-605.	1.4	5
184	Disease evolution and heterogeneity in bilateral breast cancer. American Journal of Cancer Research, 2016, 6, 2611-2630.	1.4	5
185	Chronic cholecystitis in elderly patients. Correlation of the severity of inflammation with the number and size of the stones. In Vivo, 2008, 22, 269-72.	1.3	5
186	Laparoscopic repair of giant paraesophageal hernia with synthetic mesh: 45 consecutive cases. American Surgeon, 2012, 78, 432-5.	0.8	5
187	What parameters affect pain in core biopsy?. European Radiology, 2008, 18, 1144-1145.	4.5	4
188	Ductal Endoscopy of the Breast: More Painful at the Luteal Phase?. Pain Practice, 2009, 9, 221-224.	1.9	4
189	Comparison of molecular markers expression in vacuum-assisted biopsies and surgical specimens of human breast carcinomas. Pathology Research and Practice, 2010, 206, 30-33.	2.3	4
190	Lobular Breast Cancer in Men: Case Report and Review of the Literature. Oncology Research and Treatment, 2010, 33, 698-700.	1.2	4
191	Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer. International Journal of Cardiology, 2012, 154, 341-344.	1.7	4
192	Beta-Thalassemia Major: Does It Confer Particularities to the Breast?. Breast Journal, 2013, 19, 124-125.	1.0	4
193	Pseudomamma of the inguinal region in a female patient: A case report. International Journal of Surgery Case Reports, 2015, 12, 71-74.	0.6	4
194	The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study. International Journal of Clinical Oncology, 2019, 24, 411-419.	2.2	4
195	Androgen Receptor and <i>PIM1</i> Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer. Cancer Genomics and Proteomics, 2021, 18, 147-156.	2.0	4
196	Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study. PLoS ONE, 2016, 11, e0164013.	2.5	4
197	The fate of BRCA1-related germline mutations in triple-negative breast tumors. American Journal of Cancer Research, 2017, 7, 98-114.	1.4	4
198	The Mutational Landscape of Early-Onset Breast Cancer: A Next-Generation Sequencing Analysis. Frontiers in Oncology, 2021, 11, 797505.	2.8	4

#	ARTICLE	IF	CITATIONS
199	Management of advanced stage uterine sarcomas: a bone of contention. <i>European Journal of Gynaecological Oncology (discontinued)</i> , 2009, 30, 483-92.	0.2	4
200	Evaluation of pain experienced during breast ductal endoscopy. <i>Surgery Today</i> , 2008, 38, 886-889.	1.5	3
201	Lobular Neoplasia in Vacuum-Assisted Breast Biopsy: Extended Protocols and Underestimation. <i>American Journal of Roentgenology</i> , 2008, 190, W272-W272.	2.2	3
202	Merkel cell carcinoma in pelvic lymph nodes after surgical staging for endometrial cancer: A case report and review of the literature. <i>International Journal of Surgery Case Reports</i> , 2012, 3, 340-342.	0.6	3
203	Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1776-1780.	1.3	3
204	Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 80-87.	4.4	3
205	Supportive medication in cancer during pregnancy. <i>BMC Pregnancy and Childbirth</i> , 2020, 20, 747.	2.4	3
206	Axitinib as a third or further line of treatment in renal cancer: a single institution experience. <i>BMC Urology</i> , 2020, 20, 60.	1.4	3
207	Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit. <i>Cancers</i> , 2021, 13, 763.	3.7	3
208	Paraneoplastic cerebellar degeneration in platinum-responsive endometrial cancer: A case report and review of literature. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100826.	0.6	3
209	Reversibility of Renal Impairment of Multiple Myeloma Patients Treated with Bortezomib-Based Regimens: Identification of Predictive Factors.. <i>Blood</i> , 2008, 112, 1725-1725.	1.4	3
210	Screening in the Era of Economic Crisis: Misperceptions and Misuse from a Longitudinal Study on Greek Women Undergoing Benign Vacuum-assisted Breast Biopsy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 5023-5029.	1.2	3
211	Vacuum-assisted breast biopsy: insight into stress-induced endocrine events. <i>In Vivo</i> , 2007, 21, 1081-4.	1.3	3
212	Vacuum-assisted breast biopsy in nonpalpable solid breast lesions without microcalcifications: the Greek experience. <i>Diagnostic and Interventional Radiology</i> , 2008, 14, 127-30.	1.5	3
213	Excisional breast biopsy under local anesthesia: stress-related neuroendocrine, metabolic and immune reactions during the procedure. <i>In Vivo</i> , 2009, 23, 649-52.	1.3	3
214	Prophylactic mastectomy: an appraisal. <i>American Surgeon</i> , 2013, 79, 205-12.	0.8	3
215	Vacuum-assisted breast biopsy in close proximity to the skin: a case report. <i>Journal of Medical Case Reports</i> , 2008, 2, 165.	0.8	2
216	A Woman with Breast Cancer and Severe Impaired Lactose Tolerance: An Intriguing Therapeutic Dilemma. <i>Breast Journal</i> , 2012, 18, 628-629.	1.0	2

#	ARTICLE	IF	CITATIONS
217	Gynecologic oncology patients in the surgical high dependency unit: an analysis of indications. Archives of Gynecology and Obstetrics, 2014, 290, 335-339.	1.7	2
218	Cumulative BRCA mutation analysis in the Greek population confirms that homogenous ethnic background facilitates genetic testing. Hereditary Cancer in Clinical Practice, 2015, 13, 17.	1.5	2
219	<p>Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a caseâ€“control study</p>. OncoTargets and Therapy, 2019, Volume 12, 4195-4202.	2.0	2
220	ABREAST: a prospective, real-world study on the effect of nab-paclitaxel treatment on clinical outcomes and quality of life of patients with metastatic breast cancer. Breast Cancer Research and Treatment, 2020, 182, 85-96.	2.5	2
221	<p>Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?</p>. Therapeutics and Clinical Risk Management, 2020, Volume 16, 141-146.	2.0	2
222	Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer. Cancer Genomics and Proteomics, 2020, 17, 181-193.	2.0	2
223	Adjuvant Treatment of Elderly Breast Cancer Patients: Offer the Best Chances of Cure. Breast Care, 2022, 17, 71-80.	1.4	2
224	Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting. Current Oncology, 2021, 28, 1143-1152.	2.2	2
225	Safety outcomes from monarchE: Phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer. Breast, 2021, 56, S23-S24.	2.2	2
226	BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients. Current Oncology, 2021, 28, 4446-4456.	2.2	2
227	Ruptured cystadenoma of a duplicated appendix. American Surgeon, 2010, 76, 341-3.	0.8	2
228	Neurofibromatosis 1 and breast cancer: be alert. American Surgeon, 2012, 78, E446-7.	0.8	2
229	High-throughput Proteomic Profiling of Male Breast Cancer Tissue. Cancer Genomics and Proteomics, 2022, 19, 229-240.	2.0	2
230	Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study. Histology and Histopathology, 2015, 30, 1129-41.	0.7	2
231	Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial. British Journal of Cancer, 2022, 127, 695-703.	6.4	2
232	KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer.. Journal of Clinical Oncology, 2022, 40, TPS1118-TPS1118.	1.6	2
233	Lesions of â€œUncertain Malignant Potentialâ€“Diagnosed by Vacuum-Assisted Breast Biopsy: An Unclear Management?. Annals of Surgical Oncology, 2008, 15, 2053-2054.	1.5	1
234	Cores with microcalcifications in DCIS diagnosis: how many cores make the difference?. European Radiology, 2008, 18, 2398-2398.	4.5	1

#	ARTICLE	IF	CITATIONS
235	PREDICTORS OF PAIN DURING OPEN BREAST BIOPSY UNDER LOCAL ANESTHESIA: IS THERE SUCH A THING?. Pain Practice, 2008, 8, 151-151.	1.9	1
236	Imprint cytology of vacuum-assisted breast biopsy specimens: a rapid diagnostic tool in non-palpable solid lesions. Cytopathology, 2008, 19, 311-315.	0.7	1
237	Fine-needle aspiration breast biopsy: Analysis of pain. Diagnostic Cytopathology, 2009, 37, 74-75.	1.0	1
238	Spider Bite on a Male Breast: A Rare Case in the Capital. Breast Journal, 2009, 15, 208-209.	1.0	1
239	Diagnosis of papillary lesions in breast biopsy: is conservative management justified?. American Journal of Surgery, 2009, 197, 550.	1.8	1
240	Mucocelelike Lesions and Vacuum-Assisted Breast Biopsy: Advantages and Particularities. American Journal of Roentgenology, 2011, 196, W665-W665.	2.2	1
241	Investigating the Clinical Relevance of Genomic Characteristics in Luminal a and B Breast Cancer (Bc). Annals of Oncology, 2014, 25, iv87.	1.2	1
242	Clinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting. Annals of Oncology, 2019, 30, v118.	1.2	1
243	Discrepancies of current recommendations in breast cancer follow-up: a systematic review. Breast Cancer, 2019, 26, 681-686.	2.9	1
244	Response of an oncology unit in the midst of the COVID-19 outbreak. Journal of Oncology Pharmacy Practice, 2020, 26, 1947-1952.	0.9	1
245	318P The real-world Hellenic disease management patterns with everolimus (EVE) for women with hormone-receptor-positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer (aBC): The MIRROR™ study. Annals of Oncology, 2020, 31, S370.	1.2	1
246	Tumor Genotyping and Homologous Recombination Repair Gene Variants in Patients With Epithelial Ovarian Cancer: Is Pathogenic Enough?. Frontiers in Oncology, 2021, 11, 683057.	2.8	1
247	Phase I/II Study of Lenalidomide, Intermediate Dose Dexamethasone and Low Dose Cyclophosphamide (RDC) for the Treatment of Patients with Primary Systemic Amyloidosis (AL).. Blood, 2008, 112, 1734-1734.	1.4	1
248	Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. Oncotarget, 2020, 11, 1-14.	1.8	1
249	Lenalidomide Administration In Patients With POEMS Syndrome. Blood, 2013, 122, 3235-3235.	1.4	1
250	Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Is Able to Distinguish Diffuse from Normal MRI Pattern of Marrow Involvement in Patients with Multiple Myeloma. Blood, 2014, 124, 3461-3461.	1.4	1
251	Clinical and biological implications of Hippo pathway dysregulation in sarcomas. Forum of Clinical Oncology, 2019, 9, 11-16.	0.2	1
252	Tumor dissemination after laparoscopic surgery for an unsuspected endometrial stromal tumor. European Journal of Gynaecological Oncology (discontinued), 2011, 32, 362-3.	0.2	1

#	ARTICLE	IF	CITATIONS
253	Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100953.	0.6	1
254	Advances in Gynecological Cancers. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6152.	4.1	1
255	Lesions Too Close to the Chest Wall: A Relative Contraindication for Vacuum-Assisted Breast Biopsy. <i>American Journal of Roentgenology</i> , 2008, 190, W270-W270.	2.2	0
256	Hormone Therapies. , 0, , 159-186.		0
257	Sampling lobular neoplasia of the breast: underestimation despite technical success?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 454, 715-716.	2.8	0
258	Early Breast Cancer Diagnosis in Europe, 2007: Disastrous Exceptions Exist. <i>Breast Journal</i> , 2009, 15, 101-101.	1.0	0
259	Breast cancer: is there a need for biopsy of metastases?. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 125-128.	0.5	0
260	Newly Diagnosed Multiple Myeloma is Associated with Hypercoagulability and High Risk of VTE The ROADMAP Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S76-S77.	0.4	0
261	RAD Regimen Increases Bone Formation and Reduces Bone Resorption and Angiogenesis in Patients with Newly Diagnosed Myeloma: Results of a Phase 2 Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e143.	0.4	0
262	Intrinsic tumor features underlying clinical subtype discordance in early breast cancer. <i>Annals of Oncology</i> , 2017, 28, v55-v56.	1.2	0
263	Evaluation of chemotherapy response score and lymphocytic infiltration as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2018, 29, viii346.	1.2	0
264	Actionable mutations and overall survival in 3,211 patients with cancer: The Hellenic cooperative oncology group precision medicine initiative. <i>Annals of Oncology</i> , 2018, 29, viii664.	1.2	0
265	P1577Cancer therapeutic related vaso- and cardio-toxicity in patients receiving chemotherapy for breast cancer. <i>European Heart Journal</i> , 2018, 39, .	2.2	0
266	P1573Chemotherapy-induced vasotoxicity in patients undergoing therapy for breast cancer. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
267	The learning curve of breast lesion excision system: Balancing patient's safety and surgical training. <i>Breast Journal</i> , 2020, 26, 803-805.	1.0	0
268	GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-programmed death (PD)-1, versus investigator's choice (IC) chemotherapy in 2 line recurrent or metastatic cervical cancer. <i>Gynecologic Oncology</i> , 2020, 159, 160-161.	1.4	0
269	84P Actual 5-year survival of dose-dense sequential adjuvant chemotherapy in early breast cancer (BC) patients treated in the post-trastuzumab era: A pooled analysis of 3 clinical trials. <i>Annals of Oncology</i> , 2020, 31, S43.	1.2	0
270	Nephrotoxicity in patients with cancer treated with immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2021, 39, e14558-e14558.	1.6	0

#	ARTICLE	IF	CITATIONS
271	Safety outcomes from monarchE: phase 3 study of abemaciclib combined with endocrine therapy (ET) for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer (EBC). Senologie - Zeitschrift für Mammadiagnostik Und -therapie, 2021, 18, .	0.0	0
272	CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience. Medical Sciences (Basel), Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702 Td	2.9	0
273	Effect Of Exercise On Physical Performance And Quality Of Life In Cancer Patients During Chemotherapy. Medicine and Science in Sports and Exercise, 2021, 53, 473-473.	0.4	0
274	Exercise Training-induced Hormonal And Lean Body Mass Changes In Breast Cancer Patients Undergoing Chemotherapy. Medicine and Science in Sports and Exercise, 2021, 53, 474-474.	0.4	0
275	Immunoexpression of Macrophage Inflammatory Protein-1 Alpha on Bone Marrow Trepine Biopsies Correlates with the Extent of Bone Disease in Newly Diagnosed Patients with Multiple Myeloma. Blood, 2008, 112, 5119-5119.	1.4	0
276	Treatment of Patients with Relapsed/Refractory Multiple Myeloma (MM) with Lenalidomide and Dexamethasone with or with Bortezomib Depending on Prior Neurotoxicity: Prospective Evaluation of the Impact of Cytogenetic Abnormalities and Assessment of Bone Met.. Blood, 2008, 112, 1726-1726.	1.4	0
277	Preserved Levels Of Uninvolved Immunoglobulins Are Associated With Better Overall Survival In Patients With Multiple Myeloma Independently Of Disease Burden: A Role For The Immune System?. Blood, 2013, 122, 1866-1866.	1.4	0
278	Evaluation of the Revised International Staging System (R-ISS) in an Independent Cohort of Unselected Patients with Multiple Myeloma. Blood, 2015, 126, 3045-3045.	1.4	0
279	Newly Diagnosed Multiple Myeloma Is Associated with Enhanced TF Pathway Activation, Thrombin Generation and Increased Concentration of Procoagulant Microparticles. Blood, 2015, 126, 1074-1074.	1.4	0
280	Lenalidomide, Adriamycin, and Dexamethasone (RAD) As Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Eligible for Autologous Transplantation (ASCT): A Phase 2 Study from the Greek Myeloma Study Group. Blood, 2016, 128, 4488-4488.	1.4	0
281	What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience. Current Oncology, 2021, 28, 4862-4873.	2.2	0
282	A Prospective Study and Identification of Genomewide Association Markers of Familial Predisposition to Plasma Cell Dyscrasias. Blood, 2020, 136, 8-8.	1.4	0
283	Breast lesions in patients with Mazabraud or McCune-Albright syndrome. American Surgeon, 2011, 77, E7-8.	0.8	0
284	Dual carcinoma of the breast with neuroendocrine differentiation. American Surgeon, 2012, 78, E457-8.	0.8	0
285	Immunohistochemical expression of sex steroid hormone receptors, cell cycle regulators and angiogenesis factors in intraductal papillary mucinous neoplasms: an explorative study. Anticancer Research, 2015, 35, 1049-56.	1.1	0
286	Molecular testing for prostate cancer in Greek patients.. Journal of Clinical Oncology, 2022, 40, 170-170.	1.6	0